Disordered haematopoiesis and athero-thrombosis

AJ Murphy, AR Tall - European heart journal, 2016 - academic.oup.com
European heart journal, 2016academic.oup.com
Atherosclerosis, the major underlying cause of cardiovascular disease, is characterized by a
lipid-driven infiltration of inflammatory cells in large and medium arteries. Increased
production and activation of monocytes, neutrophils, and platelets, driven by
hypercholesterolaemia and defective high-density lipoproteins-mediated cholesterol efflux,
tissue necrosis and cytokine production after myocardial infarction, or metabolic
abnormalities associated with diabetes, contribute to atherogenesis and athero-thrombosis …
Abstract
Atherosclerosis, the major underlying cause of cardiovascular disease, is characterized by a lipid-driven infiltration of inflammatory cells in large and medium arteries. Increased production and activation of monocytes, neutrophils, and platelets, driven by hypercholesterolaemia and defective high-density lipoproteins-mediated cholesterol efflux, tissue necrosis and cytokine production after myocardial infarction, or metabolic abnormalities associated with diabetes, contribute to atherogenesis and athero-thrombosis. This suggests that in addition to traditional approaches of low-density lipoproteins lowering and anti-platelet drugs, therapies directed at abnormal haematopoiesis, including anti-inflammatory agents, drugs that suppress myelopoiesis, and excessive platelet production, rHDL infusions and anti-obesity and anti-diabetic agents, may help to prevent athero-thrombosis.
Oxford University Press